Stockscreener 앱 받기
1.25
2.33%
-0.04
전일 마감가:
$1.29
열려 있는:
$1.28
하루 거래량:
1.03M
Relative Volume:
0.14
시가총액:
$423.15M
수익:
$4.47M
순이익/손실:
$-71.67M
주가수익비율:
-5.3926
EPS:
-0.2318
순현금흐름:
$-59.58M
1주 성능:
-8.03%
1개월 성능:
-8.70%
6개월 성능:
-24.10%
1년 성능:
+7.69%
1일 변동 폭
$1.24
$1.28
1주일 범위
$1.24
$1.385
52주 변동 폭
$0.931
$2.725
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.25 | 436.69M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
471.68 | 119.94B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
647.18 | 68.27B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
898.15 | 53.28B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.18 | 38.91B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
266.48 | 35.65B | 4.29B | 577.22M | 641.34M | 4.2086 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Canaccord Genuity | Buy |
| 2026-03-11 | 개시 | Oppenheimer | Outperform |
| 2024-10-15 | 개시 | Maxim Group | Buy |
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
OCGN stock holds attention as Ocugen updates its pipeline - Ad-hoc-news.de
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen (OCGN) targets 250M-share authorization increase tied to $130M converts - Stock Titan
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Why Did OCGN Stock Rise Today? - Stocktwits
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Has Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Future - Kavout | AI
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data - Stocktwits
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Ocugen licenses gene therapy to Roots Pharmaceutica - BioXconomy
symbol__ Stock Quote Price and Forecast - CNN
Why Is Ocugen (NASDAQ:OCGN) Back on the Penny Stock Radar? - Kalkine Media
Ocugen Signs $255M MENA Licensing Deal for OCU400 Gene Therapy to Treat Retinitis Pigmentosa - Minichart
Ocugen signs OCU400 MENA license agreement - grafa.com
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa - Ocugen, Inc.
Ocugen (OCGN) Secures Licensing Agreement for OCU400 in MENA Reg - GuruFocus
Ocugen Signs Term Sheet to License Retinitis Pigmentosa Gene Therapy to Roots Pharmaceutical, Al-Dhow in MENA Region - Moomoo
Ocugen (NASDAQ: OCGN) lines up OCU400 MENA license with $4M fees and 22% royalty - Stock Titan
Ocugen signs term sheet for OCU400 gene therapy in MENA region By Investing.com - Investing.com South Africa
Ocugen signs term sheet for OCU400 gene therapy in MENA region - Investing.com Nigeria
Ocugen Announces Binding Term Sheet for OCU400 License Deal in MENA Region with Roots Pharmaceutical - Quiver Quantitative
Gene therapy for inherited blindness set for MENA launch under Ocugen–Roots pact - Stock Titan
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances - Yahoo Finance
Ocugen at Piper Sandler ophthalmology day: gene therapy push advances By Investing.com - Investing.com Canada
Ocugen at Piper Sandler ophthalmology day: gene therapy push advances - Investing.com
Ocugen’s Triple-Threat Pipeline: A $130M Cash Injection and a Summer of Make-or-Break Data - ad-hoc-news.de
Ocugen stock stays tied to pipeline progress. Nasdaq listing keeps the US angle clear. - Ad-hoc-news.de
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen to Participate in Upcoming July Industry Conferences - The Manila Times
Ocugen’s July retina conference talks include OCU410 phase 2 results - Stock Titan
Ocugen, Inc. pursues gene therapy innovation to address rare vision loss conditions - Traders Union
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 2500 Growth Benchmark - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 2000 Index - marketscreener.com
OCGN Stock Grinds Higher As Traders Track Tight Range - StocksToTrade
Ocugen’s CFO Makes a Rare Open-Market Buy as Institutional Investors Pile In Ahead of Key Gene The - AD HOC NEWS
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 2000 Value Benchmark - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell Microcap Value Benchmark Index - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 2000 Growth Benchmark - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 3000E Growth Benchmark - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 3000E Index - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell Microcap Index - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Ocugen, Inc.(NasdaqCM: OCGN) added to Russell 3000 Index - marketscreener.com
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
OCGN Stock Holds Buy Rating As Analyst Sees Key Catalysts Ahead - StocksToTrade
Enterprise value to EBITDA forward of Ocugen, Inc. – NASDAQ:OCGN - TradingView
Price to book forward of Ocugen, Inc. – NASDAQ:OCGN - TradingView
Ocugen Inc Actuals & Estimates (NASDAQ:OCGN) - TradingView
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
오큐젠 주식 (OCGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Zhang Junge | Director |
Apr 01 '26 |
Option Exercise |
0.79 |
194,134 |
154,303 |
1,359,316 |
0.46%
자본화:
|
볼륨(24시간):